| Stage | GMED | % of rev | HALO | % of rev | Gap · A − B |
|---|---|---|---|---|---|
| Revenue | $764M | 100.00% | $493M | 100.00% | GMED ×1.55 |
| Gross profit | $531M | 69.50% | $410M | 83.27% | HALO +13.8pp |
| Operating income | $178M | 23.25% | $295M | 59.83% | HALO +36.6pp |
| Pre-tax income | $183M | 24.00% | $291M | 58.95% | HALO +35.0pp |
| Net income | $141M | 18.48% | $247M | 50.11% | HALO +31.6pp |
| Stage | GMED | HALO | Gap · A − B |
|---|---|---|---|
| Revenue | $764M100.00% | $493M100.00% | GMED ×1.55 |
| Gross profit | 69.50%$531M | 83.27%$410M | HALO +13.8pp |
| Operating income | 23.25%$178M | 59.83%$295M | HALO +36.6pp |
| Pre-tax income | 24.00%$183M | 58.95%$291M | HALO +35.0pp |
| Net income |
| 18.48%$141M |
| 50.11%$247M |
| HALO +31.6pp |
None
No disclosed counterparties: GMED.